Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer

Paul Sabbatini, MD
Published: Thursday, Nov 09, 2017



Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dose-dense therapy or every-3-week therapy can now be used in several additional combinations in the primary therapy setting. A variety of combinations and strategies are being attempted, which can be difficult to do with intraperitoneal (IP) chemotherapy, explains Sabbatini.

IP chemotherapy is traditionally used to treat patients with ovarian cancer and can treat other gynecologic malignancies, except endometrial or cervical cancers, says Sabbatini.


Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Dose-dense therapy or every-3-week therapy can now be used in several additional combinations in the primary therapy setting. A variety of combinations and strategies are being attempted, which can be difficult to do with intraperitoneal (IP) chemotherapy, explains Sabbatini.

IP chemotherapy is traditionally used to treat patients with ovarian cancer and can treat other gynecologic malignancies, except endometrial or cervical cancers, says Sabbatini.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x